EUVIMEDEUVIMED entdecken
Multizentrische Studie

Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience

Sukh Makhnoon iD, Ang Gao, Jessica L Lee, Puja Umaretiya iD, Caitlyn Miller, Song Zhang, Arthi Sridhar, Erin L Williams, Dana L Dornsife, Robert G Johnson, Ashley Santaniello, Loren Bryant und 11 weitere

Cancer · 15.11.2026 · 132 (22)

DOI: 10.1002/cncr.70625 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 09.11.2026. Verfasst von Sukh Makhnoon und 22 weiteren Autor:innen. Beteiligte Einrichtung: Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic, Insurance, Health, Reimbursement. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas, Robert A. Winn Excellence in Clinical Trials Award Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials add to the financial burden of cancer care. To expand equitable access to trials, from 2006 to 2024 the Lazarex Cancer Foundation reimbursed nonmedical expenses related to therapeutic cancer clinical trial participation.

Methods

Eligible patients were enrolled in a cancer treatment trial and had a household income of ≤700% of the federal poverty level. Expense reimbursement occurred at 50%, 75%, and 100% according to income level. This study analyzed the type, timing, and amounts (in 2024 dollars) of reimbursed expenses for trial participants. Associations between patient/trial characteristics, reimbursed amounts, and distance traveled were evaluated via t ‐tests, analysis of variance, and multivariate linear regression.

Results

Overall, 2826 individuals (64% non‐Hispanic White, 97% with health insurance, with a median household income of $50,948) received at least one reimbursement. Median total per‐patient reimbursement was $2128, median trial participation duration was 4.3 months, and monthly reimbursed amounts declined substantially throughout trial participation. Types of reimbursement varied by patient income: internet, ground transportation, and child/elder care were more common at lower income levels, whereas lodging and airfare were more common for higher incomes. In multivariate analysis, monthly reimbursed amount was greater among middle‐tier household income quartiles ( p = .003), greater distance to trial site ( p < .001), and phase 1 trials ( p = .001). The proportion of patients participating across income levels remained stable over time.

Conclusions

Reimbursement needs during cancer clinical trial participation are dynamic and closely tied to both socioeconomic status and logistical burden, particularly travel distance and trial intensity. Financial support for these expenses may enhance trial accessibility and retention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials as TopicInsurance, Health, ReimbursementHumansFemaleMaleMiddle AgedAgedIncomeAdultHealth Services Accessibility

Stichwörter der Autor:innen

cancer clinical trialsfinancial toxicitynonmedical costsracial/ethnic minoritiesreimbursementsponsor

Autor:innen und Institutionen

  • Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Peter O'Donnell Jr. School of Public Health, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Children's Health, Dallas, Texas, USA.
  • Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Lazarex Cancer Foundation, Danville, California, USA.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Sukh Makhnoon, Puja Umaretiya, Navid Sadeghi, Hala T Borno, David E Gerber

Förderung

  • Cancer Prevention and Research Institute of Texas
  • Robert A. Winn Excellence in Clinical Trials Award Program

Zitieren

APA

Makhnoon, S., Gao, A., Lee, J. L., Umaretiya, P., Miller, C., Zhang, S., Sridhar, A., Williams, E. L., Dornsife, D. L., Johnson, R. G., Santaniello, A., Bryant, L., Sadeghi, N., Nipp, R. D., Moy, B., Borno, H. T., Zhang, S., Spicer, D. V., Leavey, P. J., …, & Gerber, D. E. (2026). Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience. Cancer, 132(22). https://doi.org/10.1002/cncr.70625

Vancouver

Makhnoon S, Gao A, Lee JL, Umaretiya P, Miller C, Zhang S, et al. Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience. Cancer. 2026;132(22). doi:10.1002/cncr.70625

BibTeX
@article{Makhnoon2026,
  author = {Makhnoon, Sukh and Gao, Ang and Lee, Jessica L and Umaretiya, Puja and Miller, Caitlyn and Zhang, Song and Sridhar, Arthi and Williams, Erin L and Dornsife, Dana L and Johnson, Robert G and Santaniello, Ashley and Bryant, Loren and Sadeghi, Navid and Nipp, Ryan D and Moy, Beverly and Borno, Hala T and Zhang, Sylvia and Spicer, Darcy V and Leavey, Patrick J and Kitzman, Heather E and McNeill, Lorna Haughton and Guerra, Carmen E and Gerber, David E},
  title = {Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {22},
  doi = {10.1002/cncr.70625}
}
Kostenlos starten →